Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
09/20/17
Single Inhaler Triple Therapy Met Study Primary Endpoint Demonstrating Reduction in Exacerbations Compared with Dual Therapies Anoro Ellipta and Relvar/Breo Ellipta in Patients with COPD Theravance Biopharma Entitled to Receive 85% Economic Interest in Trelegy Ellipta Royalties Paid by
09/19/17
DUBLIN , Sept. 19, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET .
09/19/17
Theravance Biopharma Entitled to Receive 85% Economic Interest in Trelegy Ellipta Royalties Paid by GlaxoSmithKline as Part of Agreement with Innoviva DUBLIN , Sept. 19, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the US Food and
09/18/17
Theravance Biopharma Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva DUBLIN, Ireland , Sept. 18, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that GlaxoSmithKline plc
09/05/17
DUBLIN , Sept. 5, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12, 2017 at 8:00 a.m. ET .
08/08/17
Meaningful Clinical Readouts Underpin Progress in Key Programs Additional Milestones Anticipated in Remainder of 2017 and 2018 DUBLIN , Aug. 8, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today reported financial results for the second
08/08/17
Evidence of Localized Target Engagement after Four Weeks of Treatment Minimal Systemic Exposure No Evidence of Systemic Immunosuppression or Infections Company Plans to Progress TD-1473 into Induction and Maintenance Study in 2018 DUBLIN , Aug. 8, 2017 /PRNewswire/ --  Theravance Biopharma, Inc.
08/02/17
Improvements in Symptoms and Normalized Gastric Emptying Demonstrated in both Diabetic and Idiopathic Gastroparesis Patients DUBLIN, Ireland , Aug. 2, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced positive results from a
08/01/17
DUBLIN , Aug. 1, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended June 30, 2017 after market close on Tuesday, August 8, 2017 .
07/31/17
Experienced Life Science Leader with Track Record of Business Development and Portfolio Management Successes DUBLIN , July 31, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced the appointment of Shehnaaz Suliman , MD, to the